Clinical Trial

T-cell Therapy in Patients With PML

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
There is no approved standard treatment für progressive multifocal leukoencephalopathy (PML). The sponsor of the study is developing a new treatment. For this reason, the investigational medicinal product (IMP) called 'human allogenic HPyV-2-specific T cells' is to be tested in this study. The sponsor wants to find out whether the IMP is safe, influences the neurological status and improves the quality of the life of patients . It is to be investigated whether the IMP can be used to treat the disease and whether it could have an advantage over the standard therapy in terms of survival rate.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-19; most recent amendment 2026-02-10.
Status change: Not Yet Recruiting → Recruiting 2026-02-10
Trial Details
NCT Number NCT06990087
Lead Sponsor Hannover Medical School
Conditions Progressive Multifocal Leucoencephalopathy (PML)
Enrollment 23 participants
Start Date 2026-02-06
Primary Completion 2027-11 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-02-12